| Residential College | false |
| Status | 已發表Published |
| Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy | |
Kwok, H. F.  ; Botkjaer, K. A.; Tape, C. J.; Huang, Y.; McCafferty, J.; Murphy, G.
| |
| 2014-04-01 | |
| Source Publication | Protein engineering, design & selection : PEDS Oxford University Press
 |
| ISSN | 1741-0126 |
| Pages | 179-190 |
| Abstract | We previously showed that a human anti-TACE antibody, D1(A12), is a potent inhibitor of TNF-α converting enzyme (TACE) ectodomain proteolysis and has pharmacokinetic properties suitable for studies of the inhibition of TACE-dependent growth factor shedding in relation to possible therapeutic applications. However, the lack of murine TACE immunoreactivity limits pre-clinical in vivo studies to human xenograft models which are poor analogies to in situ pathology and are not considered clinically predictive. Here, to overcome these limitations, we set out to develop a 'mouse and human cross-reactive' specific anti-TACE antibody. We first re-investigated the originally selected anti-TACE ectodomain phage-display clones, and isolated a lead 'mouse-human cross-reactive' anti-TACE scFv, clone A9. We reformatted scFv-A9 into an IgG2 framework for comprehensive biochemical and cellular characterization and further demonstrated that A9 is an exosite TACE inhibitor. However, surface plasmon resonance analysis and quenched-fluorescent (QF) peptide assay indicated that IgG reformatting of A9 caused low binding affinity and an 80-fold reduction in TACE ectodomain inhibition, severely limiting its efficacy. To address this, we constructed second generation phage-display randomization libraries focused on the complementarity-determining region 3, and carried out affinity selections shuffling between human and mouse TACE ectodomain as antigen in addition to an off-rate selection to increase the chance of affinity improvement. The bespoke 'three-step' selections enabled a 100-fold affinity enhancement of A9 IgG, and also improved its IC50 in a QF peptide assay to 0.2 nM. In human and mouse cancer cell assays, matured A9 IgG showed significant cell-surface TACE inhibition as a monotherapy or combination therapy with chemotherapeutic agent. Collectively, these data suggest that we successfully developed an exosite inhibitor of TACE with sub-nanomolar affinity, which possesses both murine and human immunoreactive properties that can be used for in vivo application in murine pre-clinical cancer models. |
| Keyword | anti-TACE antibody exosite immunoreactivity phage-display randomization libraries sub-nanomolar affinity |
| Language | 英語English |
| The Source to Article | PB_Publication |
| PUB ID | 11702 |
| Document Type | Journal article |
| Collection | DEPARTMENT OF BIOMEDICAL SCIENCES Faculty of Health Sciences Cancer Centre |
| Corresponding Author | Kwok, H. F.; Murphy, G. |
| Recommended Citation GB/T 7714 | Kwok, H. F.,Botkjaer, K. A.,Tape, C. J.,et al. Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy[J]. Protein engineering, design & selection : PEDS Oxford University Press, 2014, 179-190. |
| APA | Kwok, H. F.., Botkjaer, K. A.., Tape, C. J.., Huang, Y.., McCafferty, J.., & Murphy, G. (2014). Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein engineering, design & selection : PEDS Oxford University Press, 179-190. |
| MLA | Kwok, H. F.,et al."Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy".Protein engineering, design & selection : PEDS Oxford University Press (2014):179-190. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment